New Hope Network is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Glanbia, Ganeden expand BC30's use in functional foods

Glanbia, Ganeden expand BC30's use in functional foods
Companies have expanded shelf-stable probiotic strain into more than 50 foods and beverages in a variety of product categories.  

Probiotics aren’t just for yogurt anymore. Thanks to the patented strain of probiotic bacteria in GanedenBC30® and its recently acknowledged FDA-GRAS status, consumers can enjoy the digestive and immune health benefits of probiotics in everything from baked goods and bars to smoothies and protein shakes. Together with its primary North American distributor, Glanbia Nutritionals (NA) Inc., Ganeden has expanded its GanedenBC30 shelf-stable probiotic strain into more than 50 foods and beverages in a variety of product categories.

Capitalizing on Glanbia’s expertise in the category, GanedenBC30 entered the Sports Nutrition market earlier this year and is now featured in top product lines. Ganeden’s probiotics are a perfect fit in the category, as the stress of repetitive exercise and heavy protein supplementation can cause immune system inhibition and digestive issues.

Ganeden and Glanbia have worked closely to introduce GanedenBC30 into innovative and novel applications, resulting in GanedenBC30’s inclusion in a variety of food, beverage and weight loss products including cereals, juices, meal replacement drinks and snacks.  

“We are very pleased with our strategic partnership with Glanbia Nutritionals,” said Mike Bush, Vice President of Sales and Marketing for Ganeden Biotech. “Glanbia’s nutritional expertise and global sales team have opened doors for GanedenBC30 and allowed us to enter into new and innovative markets.”

GanedenBC30 is extremely shelf-stable, requires no refrigeration and can be baked, boiled or frozen while retaining viability, allowing consumers to experience its health benefits in a variety of applications. GanedenBC30’s unique structure features a hardened spore inside each cell which acts as a natural protective shield against the heat and pressure of manufacturing and the strong acids in the stomach to arrive alive in the intestines, providing optimal health benefits.

“As an innovative ingredient with impressive scientific support, GandedenBC30 has been an excellent addition to our product line,” said Kevin Meyer, Vice President of Sales for Glanbia Nutritionals. “We’re excited to continue working with Ganeden to increase their current market presence and introduce GandedenBC30 into new applications and territories.”

According to a report by MarketsandMarkets, the global probiotics market is expected to be worth US$32.6 billion by 2014, and probiotics remains a top trend in food and beverage fortification. Together, Ganeden Biotech and Glanbia Nutritionals plan to grow with this market, developing new applications and products that deliver consumers clinically proven health benefits with a wide variety of choices.

About Ganeden Biotech
Founded in 1997, Cleveland, Ohio based Ganeden Biotech is at the forefront of probiotic research and product development. Ganeden has an extensive library of published studies and more than 100 patents for probiotic technologies for the food, beverage, animal health, and topical ingredients markets. The company is best known for

GanedenBC30, its patented, FDA GRAS probiotic ingredient, found in more than 50 leading food and beverage products. Ganeden helps manufacturers develop and market probiotic products and offers an extensive intellectual property portfolio with patent and trademark protection for an array of technologies all over the world.

About Glanbia Nutritionals (NA) Inc.
Glanbia Nutritionals (NA) Inc. is a division of Glanbia plc, an international nutritional solutions and cheese group, headquartered in Kilkenny, Ireland. The Group has 4,300 employees worldwide, with operations in Ireland, the UK, Germany, USA, Canada, Mexico and China, as well as strategic international joint ventures in the UK, USA and Nigeria. Glanbia is listed on both the Dublin and London Stock Exchange.

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.